The activation of TRPV4 channels has been implicated in pulmonary hypertension (Suresh et al., 2018), hyponatremia (Carreno et al., 2009; Tian et al., 2009), neurodegenerative skeletal muscle dysplasia (Auer-Grumbach et al., 2010), and bone disorders (Mizoguchi et al., 2008) and its inhibition presents a potential therapeutic strategy for pain, gastrointestinal disorders, edema, and lung diseases (Grace et al., 2017). Here, TRPV4 is linked to pulmonary arterial hypertension.